Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

FDA Places Clinical Hold on Phase 1 Trial of SC-DARIC33 in Pediatric R/R CD33+ AML

August 14th 2023

The FDA has placed a clinical hold on the phase 1 PLAT-08 trial evaluating SC-DARIC33 in pediatric and young-adult patients with relapsed/refractory CD33-positive acute myeloid leukemia.

Acute GVHD Presentation and Diagnosis

August 14th 2023

Acute GVHD presentation and diagnosis is assessed for the clinical scenario previously discussed.

The GVHD Prophylaxis Landscape

August 14th 2023

GVHD prophylaxis techniques are analyzed by the panelists.

IBI322 Shows Early Antitumor Efficacy in PD-1/PD-L1–Resistant Classical Hodgkin Lymphoma

August 13th 2023

Single-agent IBI322 elicited responses with favorable safety in patients with classical Hodgkin lymphoma that had become resistant to anti–PD-1/PD-L1 therapy, according to data from a phase 1 trial.

Extended Treatment With CAEL-101 Plus SOC Therapy Proves Safe in Light-Chain Amyloidosis

August 12th 2023

The addition of the chimeric monoclonal antibody CAEL-101 to standard therapy with cyclophosphamide, bortezomib, and dexamethasone with or without daratumumab demonstrated a manageable toxicity profile with prolonged clinical benefit in patients with amyloid light-chain amyloidosis.

Key Trials in the Treatment of Higher-Risk MDS

August 10th 2023

Dr Zeidan highlights ongoing clinical trials for treatment of higher-risk MDS.

IRAK1 and IRAK4 Inhibitors for the Treatment of Lower-Risk MDS

August 10th 2023

Dr Brunner presents updated data on the treatment of lower-risk MDS with IRAK1/IRAK4 inhibitors.

Future Directions in Chronic GvHD

August 9th 2023

Dr. Chaudhary and Dr. Merin discuss potential areas for exploration and unmet needs in the chronic GvHD treatment landscape.

Real World Data on the Use of Ruxolitinib and Treatment Selection in chronic GvHD

August 9th 2023

Discussion centered around real-world data following the approval of ruxolitinib as a treatment option for patients with chronic GvHD as well as discussing treatment selection for patients with chronic GvHD, with special consideration for treatment sequencing.

Pacritinib in Myelofibrosis: Adverse Event Management and Dosing

August 8th 2023

Shared insight on the safety profile of pacritinib and how best to mitigate or manage adverse events when they occur in patients with myelofibrosis.

Myelofibrosis: Potential Impact of Pacritinib on Anemia

August 8th 2023

Experts continue their conversation on pacritinib in myelofibrosis by reviewing its potential impact on anemia and ACVR1.

Risk Factors for Acute and Chronic GVHD

August 7th 2023

Dr. Gooptu explains the risk factors associated with both acute and chronic GVHD.

Diffuse Large B-Cell Lymphoma: Unmet Needs and Future Directions in Care

August 7th 2023

Closing out their discussion on the management of relapsed/refractory diffuse large B-cell lymphoma, expert panelists highlight unmet needs and share excitement for future evolutions in the treatment landscape.

Conditioning Regimens for Stem Cell Transplantation

August 7th 2023

Eno-Abasi Inyang, PharmD, BCPS, BCOP provides an overview of the various conditioning regimens employed for allogeneic stem cell transplantation.

Pembrolizumab Generates Sustained Responses in Relapsed/Refractory PMBCL

August 5th 2023

Pembrolizumab produced sustained antitumor activity in patients with relapsed/refractory primary mediastinal large B-cell lymphoma, according to data from the final analysis of the phase 2 KEYNOTE-170 trial.

Dr Frank on Sequencing Questions With CAR22 in Relapsed/Refractory LBCL

August 4th 2023

Matthew J. Frank, MD, PhD, discusses remaining questions regarding treatment sequencing following preliminary results from a phase 1 trial of a CD22-directed CAR-T therapy in relapsed/refractory large B-cell lymphoma.

FDA Issues CRL to BLA Resubmission for Remestemcel-L in Pediatric Steroid-Refractory aGVHD

August 4th 2023

The FDA has released a complete response letter to its biologics license application resubmission, indicating that it needs more data to support approval for remestemcel-L for the treatment of pediatric patients with steroid-refractory acute graft-vs-host disease.

FDA Approval Insights: Glofitamab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

August 3rd 2023

Dr Carlo-Stella discusses the FDA approval of glofitamab in relapsed/refractory DLBCL, key efficacy and safety findings from the NP30179 trial, and the benefits of glofitamab’s mechanism of action.

Gilteritinib/Chemotherapy Combination Safe and Effective in Newly Diagnosed AML

August 3rd 2023

The addition of the type 1 FLT3 inhibitor gilteritinib to induction and consolidation chemotherapy, followed by maintenance gilteritinib monotherapy, was safe and tolerable with promising initial efficacy in patients with newly diagnosed acute myeloid leukemia.

Oral HMAs in Lower-Risk MDS Treatment

August 3rd 2023

Dr Carraway discusses data updates on oral hypomethylating agents (HMAs) decitabine and azacitidine for the treatment of lower-risk MDS.